Long term safety of ranibizumab in neovascular age-related macular degeneration: SECURE Study

Source: Ophthalmology
Area: News
The long-term safety of intravitreal ranibizumab 0.5-mg injections in neovascular age-related macular degeneration has been assessed in a 24 month open-label, multicentre, phase IV extension study (SECURE).

Full Story →